PDF herunterladen
CC BY-NC-ND 4.0 · J Lab Physicians 2019; 11(01): 023-028
DOI: 10.4103/JLP.JLP_129_18
Original Article

Multidrug-resistant Acinetobacter septicemia in neonates: A study from a teaching hospital of Northern India

Asifa Nazir
Department of Microbiology, Government Medical College, Srinagar, Jammu and Kashmir, India
› Institutsangaben Financial support and sponsorship: Nil
› Weitere Informationen
Auch verfügbar auf
  als PDF herunterladen Lizenzen und Reprints

Abstract

BACKGROUND: Acinetobacter species are typical nosocomial pathogens causing infections and high mortality, almost exclusively in compromised hospitalized patients. Acinetobacter sp. are intrinsically less susceptible to antibiotics and have propensity to acquire resistance. Multidrug-resistant (MDR) Acinetobacter sp. blood infection in the neonatal intensive care unit patients create a great problem in hospital settings.

AIMS: A prospective data analysis was performed over a one year period of all neonates admitted with sepsis who developed Acinetobacter infection and their antibiotic susceptibility pattern was carried out.

MATERIALS AND METHODS: Blood samples of infected neonates were collected aseptically and cases of Acinetobacter septicemia were identified. Speciation of Acinetobacter species was done. Various risk factors were identified and their drug-sensitivity test was performed.

RESULTS: The incidence of neonatal septicemia due to Acinetobacter species was 13.7% (49/357). Predominant species isolated was Acinetobacter baumannii (98%). The major symptoms were lethargy and poor feeding. The major signs were tachypnea, intercostal retraction, and respiratory distress. The major fetal risk factors were low birth weight and prematurity. High degree of resistance was observed to the various antibiotics used. Majority of the isolates (95.9%) were MDR while 93.68% were resistant to carbapenems as well as extensively drug resistant. However, all the strains were sensitive to colistin.

CONCLUSION: MDR Acinetobacter septicemia in neonatal patients is becoming alarmingly frequent and is associated with significant mortality and morbidity. Therefore, rational antibiotic use is mandatory along with an effective infection control policy in neonatal intensive care areas of each hospital to control Acinetobacter infection and improve outcome.

Key words

Acinetobacter septicemia - blood culture - multidrug resistance - neonatal sepsis


Publikationsverlauf

Eingereicht: 03. Oktober 2018

Angenommen: 20. Dezember 2018

Artikel online veröffentlicht:
06. April 2020

© 2019.

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 Towner KJ. Acinetobacter: An old friend, but a new enemy. J Hosp Infect 2009;73:355-63.
  • 2 Gerner-Smidt P. Taxonomy and epidemiology of Acinetobacter infections. Rev Med Microbiol 1995;6:186-97.
  • 3 Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: Emergence of a successful pathogen. Clin Microbiol Rev 2008;21:538-82.
  • 4 Vinodkumar CS, Neelagund YF. Acinetobacter septicaemia in neonates. Indian J Med Microbiol 2004;22:71.
  • 5 Koneman EW, Allen SD, Janda WM, Schreckenberger PC, Winn WC Jr. Color Atlas and Textbook of Diagnostic Microbiology. 5th ed. Philadelphia, USA: Lippincott Williams and Wilkins; 1997. p. 253-320.
  • 6 Aktas O, Ozbek A. Prevalence and in vitro antimicrobial susceptibility patterns of Acinetobacter strains isolated from patients in intensive care units. J Int Med Res 2003;31:272-80.
  • 7 Centers for Disease Control and Prevention. Overview of drug-resistant Acinetobacter Infections in Healthcare Settings. Available from: http://www.cdc.gov/ncidod/dhqp/ar_acinetobacter.html. [Last accessed on 2009 Oct 26].
  • 8 Sinha N, Agarwal J, Srivastava S, Singh M. Analysis of carbapenem-resistant Acinetobacter from a tertiary care setting in North India. Indian J Med Microbiol 2013;31:60-3.
  • 9 Bergogne-Berezin E, Tower KJ. Acinetobacter sp. as nosocomial pathogens: Microbiological, clinical, and epidemiological features. Clin Microbial Rev 1996;9:148-65.
  • 10 Fournier PE, Richet H. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis 2006;42:692-9.
  • 11 Joly-Guillou ML. Clinical impact and pathogenicity of Acinetobacter. Clin Microbiol Infect 2005;11:868-73.
  • 12 Punpanich W, Nithitamsakun N, Treeratweeraphong V, Suntarattiwong P. Risk factors for carbapenem non-susceptibility and mortality in Acinetobacter baumannii bacteremia in children. Int J Infect Dis 2012;16:e811-5.
  • 13 Turkoglu M, Mirza E, Tunçcan ÖG, Erdem GU, Dizbay M, Yaǧcı M, et al. Acinetobacter baumannii infection in patients with hematologic malignancies in intensive care unit: Risk factors and impact on mortality. J Crit Care 2011;26:460-7.
  • 14 Lockhart SR, Abramson MA, Beekmann SE, Gallagher G, Riedel S, Diekema DJ, et al. Antimicrobial resistance among gram-negative bacilli causing infections in intensive care unit patients in the United States between 1993 and 2004. J Clin Microbiol 2007;45:3352-9.
  • 15 Bonomo RA, Szabo D. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis 2006;43 Suppl 2:S49-56.
  • 16 Gordon NC, Wareham DW. Multidrug-resistant Acinetobacter baumannii: Mechanisms of virulence and resistance. Int J Antimicrob Agents 2010;35:219-26.
  • 17 Poirel L, Nordmann P. Carbapenem resistance in Acinetobacter baumannii: Mechanisms and epidemiology. Clin Microbiol Infect 2006;12:826-36.
  • 18 Falagas ME, Koletsi PK, Bliziotis IA. The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. J Med Microbiol 2006;55:1619-29.
  • 19 Falagas ME, Karageorgopoulos DE. Pandrug resistance (PDR), extensive drug resistance (XDR), and multidrug resistance (MDR) among gram-negative bacilli: Need for international harmonization in terminology. Clin Infect Dis 2008;46:1121-2.
  • 20 European Centre for Disease Prevention and Control/European Medicines Agency. ECDC/EMEA Joint Technical Report. The Bacterial Challenge: Time to React. Stockholm, Sweden & London, United Kingdom: European Centre for Disease Prevention & Control and European Medicines Agency; 2009.
  • 21 Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012;18:268-81.
  • 22 Manchanda V, Sanchaita S, Singh N. Multidrug resistant Acinetobacter. J Glob Infect Dis 2010;2:291-304.
  • 23 Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Third Informational Supplement. Clinical and Laboratory Standards Institute; M100-S23. January, 2013.
  • 24 Arora U, Jaitwani J. Acinetobacter spp. – An emerging pathogen in neonatal septicemia in Amritsar. Indian J Med Microbiol 2006;24:81.
  • 25 Mondal GP, Raghavan M, Bhat BV, Srinivasan S. Neonatal septicaemia among inborn and outborn babies in a referral hospital. Indian J Pediatr 1991;58:529-33.
  • 26 Christo GG, Shenoy V, Matthai J, Shivananda PG, Venkatesh A. Acinetobacter sepsis in neonates. Indian Pediatr 1993;30:1413-6.
  • 27 Mishra A, Mishra S, Jaganath G, Mittal RK, Gupta PK, Patra DP, et al. Acinetobacter sepsis in newborns. Indian Pediatr 1998;35:27-32.
  • 28 Kapoor L, Randhawa VS, Deb M. Microbiological profile of neonatal septicemia in a pediatric care hospital in Delhi. J Commun Dis 2005;37:227-32.
  • 29 Prashanth K, Badrinath S. Nosocomial infections due to Acinetobacter species: Clinical findings, risk and prognostic factors. Indian J Med Microbiol 2006;24:39-44.
  • 30 Saleem AF, Ahmed I, Mir F, Ali SR, Zaidi AK. Pan-resistant Acinetobacter infection in neonates in Karachi, Pakistan. J Infect Dev Ctries 2009;4:30-7.
  • 31 Shete VB, Ghadage DP, Muley VA, Bhore AV. Acinetobacter septicemia in neonates admitted to intensive care units. J Lab Physicians 2009;1:73-6.
  • 32 De AS, Rathi MR, Mathur MM. Mortality audit of neonatal sepsis secondary to Acinetobacter. J Glob Infect Dis 2013;5:3-7.
  • 33 Villegas MV, Hartstein AI. Acinetobacter outbreaks, 1977-2000. Infect Control Hosp Epidemiol 2003;24:284-95.
  • 34 Signore C, Klebanoff M. Neonatal morbidity and mortality after elective cesarean delivery. Clin Perinatol 2008;35:361-71, vi.
  • 35 Jawad A, Heritage J, Snelling AM, Gascoyne-Binzi DM, Hawkey PM. Influence of relative humidity and suspending menstrua on survival of Acinetobacter spp. On dry surfaces. J Clin Microbiol 1996;34:2881-7.
  • 36 Sinha M, Srinivasa H, Macaden R. Antibiotic resistance profile and extended spectrum beta-lactamase (ESBL) production in Acinetobacter species. Indian J Med Res 2007;126:63-7.
  • 37 Gladstone P, Rajendran P, Brahmadathan KN. Incidence of carbapenem resistant nonfermenting gram negative bacilli from patients with respiratory infections in the intensive care units. Indian J Med Microbiol 2005;23:189-91.
  • 38 Hanberger H, Garcia-Rodriguez JA, Gobernado M, Goossens H, Nilsson LE, Struelens MJ, et al. Antibiotic susceptibility among aerobic gram-negative bacilli in intensive care units in 5 European countries. French and Portuguese ICU study groups. JAMA 1999;281:67-71.
  • 39 Turner PJ, Greenhalgh JM; MYSTIC Study Group (Europe). The activity of meropenem and comparators against Acinetobacter strains isolated from European hospitals, 1997-2000. Clin Microbiol Infect 2003;9:563-7.
  • 40 Turner PJ. Meropenem activity against European isolates: Report on the MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) 2006 results. Diagn Microbiol Infect Dis 2008;60:185-92.
  • 41 Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA, et al. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2007;51:3471-84.
  • 42 Trottier V, Segura PG, Namias N, King D, Pizano LR, Schulman CI, et al. Outcomes of Acinetobacter baumannii infection in critically ill burned patients. J Burn Care Res 2007;28:248-54.
  • 43 Peleg AY, Potoski BA, Rea R, Adams J, Sethi J, Capitano B, et al. Acinetobacter baumannii bloodstream infection while receiving tigecycline: A cautionary report. J Antimicrob Chemother 2007;59:128-31.
  • 44 Chan JD, Graves JA, Dellit TH. Antimicrobial treatment and clinical outcomes of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia. J Intensive Care Med 2010;25:343-8.
  • 45 Courvalin P. Antimicrobial drug resistance: “Prediction is very difficult, especially about the future”. Emerg Infect Dis 2005;11:1503-6.
  • 46 Pittet D. The Lowbury lecture: Behaviour in infection control. J Hosp Infect 2004;58:1-3.